新辅助化疗在Ib～IIb期宫颈癌病例中的作用

Neoadjuvant chemotherapy in stage Ib～IIb carcinoma of the cervix:long-term follow-up

目的 探讨 1周期的新辅助化疗在宫颈癌病例治疗中的作用和地位。方法 4 9例Ib～IIb期宫颈癌病例在实施宫颈癌根治术前给予 1周期新辅助化疗组 (NAC)。结果 临床有效率 6 1.2 2 %。病理证实的完全缓解 2例。平均生存时间 4 4月。结论 1周期的新辅助化疗能够产生较高的有效率 ,提高IIb期宫颈癌病例的手术成功率。对缺乏放疗设备的医疗单位 ,我们可以用NAC代替后装腔内治疗。

Objective To determine the role of neoadjuvant chemotherapy (NAC)) before radical Wertheim hysterectomy. Methods Fouty-nine previously untreated patients with stage Ib～IIb were enrolled in the study. Results The overall clinical response rate was 61.22% . Pathologic complete responses were found in 2 patients ( 4.08% ). The median survival time was 44 months in NAC treatment patients and as for survival time and survival rate there is no significant difference between two groups. Conclusion These preliminary results suggest that one course of NAC is able to produce the higher response rate and to improve the operability in patients with stage IIb cervical cancer. We could use NAC instead of pre-operative brachy-radiation in the absence of some radiation equipments.